Treating multiple sclerosis (MS) with monoclonal antibodies ... Following this, the newer anti-CD20 mAbs ocrelizumab and ofatumumab, which are currently being tested in Phase II for MS, are ...

Relapsing-remitting multiple sclerosis is an unpredictable disease marked by relapses and remissions, but there are options to help you.

Switching therapies is a common part of multiple sclerosis management and may be considered for several reasons.

If you have multiple sclerosis (MS) and are hoping to get pregnant, the news is good: MS itself does not make a pregnancy ...

Many women are diagnosed with multiple sclerosis (MS) at an age when they ... natalizumab, anti-CD20 antibodies (rituximab, ocrelizumab, ofatumumab) and cladribine. Of the cohort, 837 pregnant ...

Many women are diagnosed with multiple sclerosis (MS) at an age when they ... natalizumab, anti-CD20 antibodies (rituximab, ocrelizumab, ofatumumab) and cladribine. 837 pregnant women had not ...

Many people living with the degenerative neurological disease multiple sclerosis (MS ... "New data continue to support the use of anti-CD20 monoclonal antibodies during breastfeeding, with ...

Preliminary U.S. BRIUMVI fourth quarter and full year 2024 net product revenue of $103.6 million and $310 million, respectivelyFull Year 2025 ...

Peter Rieckmann, MD, FRCPC, Multiple Sclerosis Society of Canada Research ... Rituximab is a human/mouse chimeric IgG1κ antibody raised against CD20, which is expressed on B cells but not on ...

Many people living with the degenerative neurological disease multiple sclerosis (MS) are premenopausal women. This means ...